News
-
-
PRESS RELEASE
Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses
Telomir Pharmaceuticals, Inc. announces groundbreaking results in reversing oxidative stress challenges and cellular protection. Telomir-1 shows promise in addressing age-related diseases and viral infections -
-
PRESS RELEASE
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)
Telomir Pharmaceuticals announces potentially groundbreaking findings from preclinical progeria lifespan study demonstrating restoration of shortened lifespan and normalization of accelerated aging with Telomir-1 -
-
PRESS RELEASE
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease
Telomir Pharmaceuticals announces promising findings from copper binding studies with Telomir-1, addressing Wilson's disease and metal toxicity. Telomir-1 shows potential in preclinical models for multiple conditions -
-
PRESS RELEASE
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
Telomir Pharmaceuticals, Inc. raises $1 million in equity funding through The Starwood Trust, reinforcing financial strength. Telomir-1 shows transformative potential in addressing age-related conditions -
-
PRESS RELEASE
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1
Telomir Pharmaceuticals announces groundbreaking preclinical results showcasing Telomir-1's efficacy in reversing key parameters of Type 2 diabetes mellitus, potentially addressing insulin resistance at its root
